PMID- 24668485
OWN - NLM
STAT- MEDLINE
DCOM- 20140826
LR  - 20151119
IS  - 0171-2004 (Print)
IS  - 0171-2004 (Linking)
VI  - 220
DP  - 2014
TI  - Modulation of neurotrophin signaling by monoclonal antibodies.
PG  - 497-512
LID - 10.1007/978-3-642-45106-5_19 [doi]
AB  - The neurotrophin family is comprised of the structurally related secreted 
      proteins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
      neurotrophin-3 (NT-3), and neurotrophine-4 (NT-4). They bind and activate the 
      tyrosine kinase receptors Trk A, B, and C in a ligand-specific manner and 
      additionally bind a shared p75NTR receptor. The neurotrophins were originally 
      defined by their ability to support the survival and maturation of embryonic 
      neurons. However, they also control important physiological functions of the 
      adult nervous system including learning and memory, sensation, and energy 
      homeostasis. For example, NGF/trkA signaling is critical for normal and 
      pathological sensation of pain. Likewise, the BDNF/trkB pathway controls feeding 
      and metabolism, and its dysfunction leads to severe obesity. Antibodies can 
      modulate neurotrophin signaling. Thus, NGF blocking agents can attenuate pain in 
      several animal models, and a recombinant humanized NGF blocking antibody 
      (Tanezumab) has shown promising results in human clinical trials for 
      osteoarthritic pain. On the other hand trkB agonist antibodies can modulate food 
      intake and body weight in rodents and nonhuman primates. The power of monoclonal 
      antibodies to modulate neurotrophin signaling promises to turn the rich 
      biological insights into novel human medicines.
FAU - Rosenthal, A
AU  - Rosenthal A
AD  - Alector Inc., 953 Indiana St., San Francisco, CA, 94107, USA, Ar@alector.com.
FAU - Lin, J C
AU  - Lin JC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Handb Exp Pharmacol
JT  - Handbook of experimental pharmacology
JID - 7902231
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Nerve Growth Factors)
RN  - 9061-61-4 (Nerve Growth Factor)
RN  - EC 2.7.10.1 (Receptor, trkA)
RN  - EC 2.7.10.1 (Receptor, trkB)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Feeding and Eating Disorders/drug therapy
MH  - Humans
MH  - Nerve Growth Factor/antagonists & inhibitors
MH  - Nerve Growth Factors/*physiology
MH  - Neurodegenerative Diseases/drug therapy
MH  - Pain/drug therapy
MH  - Receptor, trkA/antagonists & inhibitors
MH  - Receptor, trkB/agonists
MH  - Signal Transduction/*physiology
EDAT- 2014/03/29 06:00
MHDA- 2014/08/27 06:00
CRDT- 2014/03/27 06:00
PHST- 2014/03/27 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/08/27 06:00 [medline]
AID - 10.1007/978-3-642-45106-5_19 [doi]
PST - ppublish
SO  - Handb Exp Pharmacol. 2014;220:497-512. doi: 10.1007/978-3-642-45106-5_19.